These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 19143947)

  • 21. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.
    Chapman AJ; Blount AL; Davis AT; Hooker RL
    Eur J Cardiothorac Surg; 2011 Dec; 40(6):1314-8; discussion 1318-9. PubMed ID: 21601468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant Factor VIIa Is Associated With Increased Thrombotic Complications in Pediatric Cardiac Surgery Patients.
    Downey L; Brown ML; Faraoni D; Zurakowski D; DiNardo JA
    Anesth Analg; 2017 May; 124(5):1431-1436. PubMed ID: 28319507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery.
    Raivio P; Suojaranta-Ylinen R; Kuitunen AH
    Ann Thorac Surg; 2005 Jul; 80(1):66-71. PubMed ID: 15975342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged prothrombin time after recombinant activated factor VII therapy in critically bleeding trauma patients is associated with adverse outcomes.
    McMullin NR; Wade CE; Holcomb JB; Nielsen TG; Rossaint R; Riou B; Rizoli SB; Kluger Y; Choong PI; Warren B; Tortella BJ; Boffard KD;
    J Trauma; 2010 Jul; 69(1):60-9. PubMed ID: 20622579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of recombinant factor VIIa (NovoSeven) in pediatric cardiac surgery.
    Niles SD; Burkhart HM; Duffey DA; Buhrman K; Burzynski J; Holt DW
    J Extra Corpor Technol; 2008 Dec; 40(4):241-8. PubMed ID: 19192753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The use of recombinant activated factor VIIa for major bleedings in open heart surgery].
    Ingimarsson JP; Onundarson PT; Valsson F; Vidarsson B; Gudbjartsson T
    Laeknabladid; 2008 Sep; 94(9):607-12. PubMed ID: 18784387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis.
    Gelsomino S; Lorusso R; Romagnoli S; Bevilacqua S; De Cicco G; Billè G; Stefàno P; Gensini GF
    Eur J Cardiothorac Surg; 2008 Jan; 33(1):64-71. PubMed ID: 17996457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of rFVIIa in intractable hemorrhage in patients on central veno-arterial ECMO].
    Vanhuyse F; Frotscher B; Lecompte T; Maureira P; Villemot JP; Folliguet T; Toussaint-Hacquard M
    Ann Fr Anesth Reanim; 2013 Oct; 32(10):665-9. PubMed ID: 23993217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant activated factor VII in critical bleeding after orthotopic liver transplantation.
    Busani S; Semeraro G; Cantaroni C; Masetti M; Marietta M; Girardis M
    Transplant Proc; 2008; 40(6):1989-90. PubMed ID: 18675109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of recombinant activated factor VII for refractory hemorrhage in pediatric patients on extracorporeal membrane oxygenation: a single center review.
    Long MT; Wagner D; Maslach-Hubbard A; Pasko DA; Baldridge P; Annich GM
    Perfusion; 2014 Mar; 29(2):163-70. PubMed ID: 23942787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass.
    Naik VN; Mazer CD; Latter DA; Teitel JM; Hare GM
    Can J Anaesth; 2003; 50(6):599-602. PubMed ID: 12826554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients.
    Tobias JD; Simsic JM; Weinstein S; Schechter W; Kartha V; Michler R
    J Intensive Care Med; 2004; 19(5):270-3. PubMed ID: 15358945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lung transplantation on cardiopulmonary support: venoarterial extracorporeal membrane oxygenation outperformed cardiopulmonary bypass.
    Ius F; Kuehn C; Tudorache I; Sommer W; Avsar M; Boethig D; Fuehner T; Gottlieb J; Hoeper M; Haverich A; Warnecke G
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1510-6. PubMed ID: 22944092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant factor VIIa as last-resort treatment of desperate haemorrhage.
    Palmason R; Vidarsson B; Sigvaldason K; Ingimarsson JP; Gudbjartsson T; Sigurdsson GH; Onundarson PT
    Acta Anaesthesiol Scand; 2012 May; 56(5):636-44. PubMed ID: 22489992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery.
    Končar IB; Davidović LB; Savić N; Sinđelić RB; Ilić N; Dragas M; Markovic M; Kostic D
    J Vasc Surg; 2011 Apr; 53(4):1032-7. PubMed ID: 21215579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery?
    Okonta KE; Edwin F; Falase B
    Interact Cardiovasc Thorac Surg; 2012 Oct; 15(4):690-4. PubMed ID: 22811512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Mini-Volume Priming During Cardiopulmonary Bypass on Clinical Outcomes in Low-Bodyweight Neonates: Less Transfusion and Postoperative Extracorporeal Membrane Oxygenation Support.
    Kim SY; Cho S; Choi E; Kim WH
    Artif Organs; 2016 Jan; 40(1):73-9. PubMed ID: 26642833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P).
    Tanaka KA; Taketomi T; Szlam F; Calatzis A; Levy JH
    Anesth Analg; 2008 Mar; 106(3):732-8, table of contents. PubMed ID: 18292410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy.
    Ekert H; Brizard C; Eyers R; Cochrane A; Henning R
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):389-95. PubMed ID: 16788315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.